Gene Therapy to Target CD19 and CD22 for B-Cell Acute Lymphocytic Leukemia and Unspecified B-Cell Lymphomas is under clinical development by Shanghai Biomed-Union Biotechnology and currently in Phase II for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia). According to GlobalData, Phase II drugs for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) have a 57% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Gene Therapy to Target CD19 and CD22 for B-Cell Acute Lymphocytic Leukemia and Unspecified B-Cell Lymphomas’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Gene Therapy to Target CD19 and CD22 for B-Cell Acute Lymphocytic Leukemia and Unspecified B-Cell Lymphomas overview

Gene therapy is under development as a third line therapy for the treatment of relapsed or refractory B cell lymphoma and relapsed or refractory acute B lymphocytic leukemia. It is administered through intravenous route. The therapy constitutes of genetically manipulated autologous T cells which express chimeric antigen receptor (CAR) targeting cells expressing B lymphocyte antigen CD19 (CD19) and cells expressing B cell receptor CD22 (CD22).

For a complete picture of Gene Therapy to Target CD19 and CD22 for B-Cell Acute Lymphocytic Leukemia and Unspecified B-Cell Lymphomas’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.